目前,丙型肝炎病毒(HCV)感染已成为诱发慢性肝炎、肝硬化和肝癌的主要病因之一。最新研究揭示,HCV感染如果持续3～ 个月以上,极难被人体自发性清除。HCV引起的轻型慢性肝炎,10年内发展为肝硬化的危险度为10％,中型慢肝为44％,中、重型慢肝和肝纤维化患者几乎100％在10年内演变为肝硬化。肝硬化一旦形成,每年则有1.4％～6.9变为肝癌,5％左右因肝衰竭、出血、感染等并发症而死亡。目前临床虽有不少抗HCV方法,但得到肯定者仅有干扰素(IFN)一种。 1.IFN适应症:目前丙肝应用IFN Currently, hepatitis C virus (HCV) infection has become one of the leading causes of chronic hepatitis, cirrhosis and liver cancer. The latest research reveals that HCV infection is extremely difficult to be spontaneously cleared if it persists for more than 3 months. HCV-induced mild chronic hepatitis develops a 10% risk of developing liver cirrhosis within 10 years, 44% of moderately slow patients, and almost 100% of patients with moderate to severe chronic liver disease and liver fibrosis evolve into cirrhosis within 10 years. Once cirrhosis is formed, 1.4% to 6.9% become liver cancer each year, and about 5% die due to complication such as liver failure, bleeding and infection. Although there are a lot of clinical anti-HCV methods, but only confirmed that only interferon (IFN) a. 1.IFN indications: the current hepatitis C application of IFN